FDA Inspection 1102650 — Rentschler Biopharma SE
The FDA completed an inspection of Rentschler Biopharma SE on August 9, 2019 in Laupheim. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- August 9, 2019
- Fiscal Year
- 2019
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Laupheim (Germany)